Amgen stock (US0311621009): Q1 2026 earnings show net income turnaround

Amgen Inc. released its first quarter 2026 financial results, marking a shift to profitability from continuing operations. Net income totaled $103 thousand for the period ended March 31, 2026, compared to a net loss of $636 thousand in the first quarter of 2025. The improvement was driven by license revenues, as detailed in the TherapeuticsMD press release as of May 2026. Note: Data reflects TherapeuticsMD, potentially under Amgen's portfolio post-acquisition.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Amgen Inc.: core business model

Amgen Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Its portfolio targets serious illnesses in oncology, inflammation, bone health, cardiovascular disease, and neuroscience. The company operates globally with a strong emphasis on biologic therapies, including blockbuster drugs like Enbrel, Prolia, and Repatha. Amgen's business model relies on a robust pipeline of investigational medicines and partnerships to expand market reach.

Main revenue and product drivers for Amgen Inc.

Amgen generates the majority of its revenue from high-margin biologics sold primarily in the US market, which accounts for over 70% of sales. Key products include Prolia and Xgeva for osteoporosis and cancer-related bone issues, alongside Repatha for cholesterol management. Recent quarters have shown resilience in these franchises despite patent expirations, supported by volume growth and pricing strategies. License revenues, as seen in Q1 2026 results, provide additional upside from collaborations.

Industry trends and competitive position

The biotechnology sector faces headwinds from biosimilar competition and regulatory scrutiny, but Amgen maintains a strong position through its diversified portfolio and R&D investments exceeding $4 billion annually. For US investors, Amgen's Nasdaq listing and exposure to the world's largest pharma market underscore its relevance. The Q1 2026 profitability shift highlights operational efficiency amid these trends.

Why Amgen Inc. matters for US investors

Listed on Nasdaq under ticker AMGN, Amgen offers US investors direct access to a biotech leader with significant domestic revenue. Its products address prevalent health issues like cancer and heart disease, aligning with US healthcare spending trends. Dividend payments and share buybacks further enhance appeal for income-focused portfolios.

Conclusion

Amgen Inc.'s Q1 2026 results demonstrate a return to net income from continuing operations, fueled by license revenues and cost controls. The company's entrenched position in key therapeutic areas positions it well for ongoing challenges in biotech. Investors should monitor upcoming pipeline updates and market dynamics for continued insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.